IntraLase & Escalon on better terms

Article

IntraLase has entered into an agreement with Escalon Medical to settle all outstanding disputes and litigation between the parties.

IntraLase has entered into an agreement with Escalon Medical to settle all outstanding disputes and litigation between the parties.

Under the terms of the agreement, IntraLase will make a payment of $9.6 million to Escalon, in exchange for all pending litigations to be dropped. Full ownership of all patents and intellectual property formerly licensed from Escalon will be obtained by IntraLase and all IntraLase obligations under the parties' license agreement will terminate. The payment will also cover all outstanding royalties owed or alleged to be owed by IntraLase to Escalon.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.